Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Neurogene (NGNE) EPS (Weighted Average and Diluted) (2018 - 2025)

Neurogene's EPS (Weighted Average and Diluted) history spans 6 years, with the latest figure at -$1.13 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) fell 14.14% year-over-year to -$1.13; the TTM value through Dec 2025 reached -$4.25, changed 0.47%, while the annual FY2025 figure was -$4.24, 0.93% up from the prior year.
  • EPS (Weighted Average and Diluted) reached -$1.13 in Q4 2025 per NGNE's latest filing, down from -$0.99 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $2.93 in Q4 2023 to a low of -$32.67 in Q3 2023.
  • Average EPS (Weighted Average and Diluted) over 3 years is -$7.77, with a median of -$1.08 recorded in 2025.
  • The largest YoY upside for EPS (Weighted Average and Diluted) was 96.46% in 2024 against a maximum downside of 133.79% in 2024.
  • A 3-year view of EPS (Weighted Average and Diluted) shows it stood at $2.93 in 2023, then tumbled by 133.79% to -$0.99 in 2024, then dropped by 14.14% to -$1.13 in 2025.
  • Per Business Quant, the three most recent readings for NGNE's EPS (Weighted Average and Diluted) are -$1.13 (Q4 2025), -$0.99 (Q3 2025), and -$1.05 (Q2 2025).